Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial, revealing that its investigational triple agonist,…
Read More
Novo Nordisk’s New Weight Loss Treatment CagriSema Shows Inferiority to Lilly’s Tirzepatide in Head-to-Head Trial
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its eagerly anticipated weight loss treatment,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, recently announced compelling Phase 2 trial results for its investigational…
Read More
Salk Institute Researchers Identify BCL6 Protein as Key Regulator for Preventing Muscle Loss During GLP-1 Weight Loss Treatments and Aging
The rapid rise of glucagon-like peptide-1 (GLP-1) receptor agonists has fundamentally altered the landscape of metabolic medicine, offering unprecedented efficacy…
Read More
Eli Lilly’s Triple Agonist Retatrutide Achieves Remarkable 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes
Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
Novo Nordisk’s latest investigational weight loss treatment, CagriSema, has failed to achieve its primary endpoint of demonstrating non-inferiority when compared…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…
Read More
Duke-NUS Medical School Scientists Discover DEAF1 Protein Mechanism as Key to Reversing Muscle Loss in Sarcopenia and Cancer Cachexia
As the global population undergoes a profound demographic shift toward an older age profile, the prevalence of age-related physical decline…
Read More
Python Blood Reveals Novel Appetite Suppressant, Offering New Hope for Weight Loss and Metabolic Health Therapies
A groundbreaking discovery by a collaborative team of scientists from the University of Colorado Boulder, Stanford University, and Baylor University…
Read More
Salk Institute Researchers Identify BCL6 Protein as Key to Preventing Muscle Loss During GLP-1 Weight Management and Aging
The rise of glucagon-like peptide-1 (GLP-1) receptor agonists has fundamentally transformed the landscape of metabolic medicine, offering unprecedented efficacy in…
Read MoreYOU MAY HAVE MISSED
